Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
The phase 3 EMPEROR-Preserved trial included 5988 adult patients with heart failure with preserved ejection fraction, with and without diabetes.
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
Omecamtiv mecarbil is a selective small molecule cardiac myosin activator.
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions.
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.